Defilade Capital Management’s Novartis NVS Stock Holding History

Defilade Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-362,816	Closed	-$50M	–	38
2025 Q4	$50M	Buy	+362,816	New	+$47.5M	6.78%	3

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Defilade Capital Management's NVS Position: Q1 2026 in Review

Defilade Capital Management sold out of Novartis (NVS) in Q1 2026, closing a stake of 362,816 shares — an estimated $50M sold.

Defilade Capital Management first reported a position in NVS in Q4 2025 and held it in 1 quarter. The position peaked at $50M in Q4 2025. 1,601 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Defilade Capital Management reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
Defilade Capital Management sold 362,816 Novartis shares in Q1 2026, an estimated $50M.
Defilade Capital Management first reported a position in Novartis in Q4 2025 and held it in 1 quarter.
Defilade Capital Management's Novartis position peaked at $50M in Q4 2025.
1,601 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Defilade Capital Management's 13F filing for Q1 2026, filed 14 May 2026.